| 主权项 |
1. A method for treating or ameliorating a disorder or condition by administering an AMPK activator, wherein the disorder or condition is selected from exercise intolerance, chronic fatigue syndrome, muscle weakness, myoclonus, myoclonus epilepsy, Kearns-Sayre syndrome, Leigh's syndrome, mitochondrial myopathy encephalopathy lactacidosis stroke (MELAS) syndrome, stroke like episodes, hypoxic states, angina pectoris, coronary ischemia and organ damage secondary to coronary vessel occlusion, intermittent claudication, multi-infarct dementia, myocardial infarction, stroke, high altitude sickness, heart failure, including congestive heart failure Duchenne's muscular dystrophy, Becker's muscular dystrophy, Freidreich's ataxia, neurological disorders, hypoxic conditions, ischemia, ischemic reperfusion injury, myocardial ischemia or infarction, cerebrovascular accidents, operative ischemia, traumatic hemorrhage, resuscitation injury, spinal cord trauma, inflammatory diseases, autoimmune disorders, Down's syndrome, Hallervorden-Spatz disease, Huntingtons chorea, Wilson's disease, diabetic angiopathy, uveitis, chronic obstructive pulmonary disease (COPD), asthma, neoplasia, Crohn's disease, inflammatory bowel disease, pancreatitis and age-related disorders, inflammatory disorders and effects, lung inflammation, organ inflammation, inflammation of the kidney or liver, and macrophage-associated inflammation; or is related to oxidative stress, mitochondrial dysfunction, free radical damage and/or metabolic inefficiency in a subject, the method comprising administering to a subject, a cell or a muscle fiber an effective amount of the AMPK activator in the form of a compound or a pharmaceutically acceptable salt, prodrug, N-oxide, solvate, hydrate or pharmaceutical composition thereof. |
